-
1
-
-
36549055697
-
Will targeted therapy hold its promise? An evidence-based review
-
Murdoch D, Sager J. Will targeted therapy hold its promise? An evidence-based review. Curr Opin Oncol 2008; 20:104-111.
-
(2008)
Curr Opin Oncol
, vol.20
, pp. 104-111
-
-
Murdoch, D.1
Sager, J.2
-
2
-
-
33748442136
-
Febrile neutropenia: Highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors
-
Timmer-Bonte JN, Tjan-Heijnen VC. Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors. Anticancer Drugs 2006; 17: 881 -889.
-
(2006)
Anticancer Drugs
, vol.17
, pp. 881-889
-
-
Timmer-Bonte, J.N.1
Tjan-Heijnen, V.C.2
-
3
-
-
34447103898
-
Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer
-
Ewer MS, O'Shaughnessy JA. Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. Clin Breast Cancer 2007; 7:600-607.
-
(2007)
Clin Breast Cancer
, vol.7
, pp. 600-607
-
-
Ewer, M.S.1
O'Shaughnessy, J.A.2
-
4
-
-
33749018219
-
Mechanisms of cutaneous toxicities to EGFR inhibitors
-
Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6:803-812.
-
(2006)
Nat Rev Cancer
, vol.6
, pp. 803-812
-
-
Lacouture, M.E.1
-
5
-
-
34147126280
-
Mucosal injury from targeted anticancer therapy
-
Keefe DM, Gibson RJ. Mucosal injury from targeted anticancer therapy. Support Care Cancer 2007; 15:483-490.
-
(2007)
Support Care Cancer
, vol.15
, pp. 483-490
-
-
Keefe, D.M.1
Gibson, R.J.2
-
6
-
-
85047694230
-
New strategies for the prevention and reduction of cancer treatment-induced diarrhea
-
Anthony L. New strategies for the prevention and reduction of cancer treatment-induced diarrhea. Semin Oncol Nurs 2003; 19 (4 Suppl 3):17-21.
-
(2003)
Semin Oncol Nurs
, vol.19
, Issue.4 SUPPL. 3
, pp. 17-21
-
-
Anthony, L.1
-
7
-
-
53649102912
-
Risk and quality of life impact of mucosal injury among colorectal cancer patients receiving FOLFOX chemotherapy [abstract]
-
Grunberg S, Hesketh P, Randolph-Jackson P, et al. Risk and quality of life impact of mucosal injury among colorectal cancer patients receiving FOLFOX chemotherapy [abstract]. Support Care Cancer 2007; 15:704.
-
(2007)
Support Care Cancer
, vol.15
, pp. 704
-
-
Grunberg, S.1
Hesketh, P.2
Randolph-Jackson, P.3
-
8
-
-
11144356545
-
Perspectives on cancer therapy-induced mucosal injury: Pathogenesis, measurement, epidemiology and consequences for patients
-
Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology and consequences for patients. Cancer Suppl 2004; 100 (Suppl):1995-2025.
-
(2004)
Cancer Suppl
, vol.100
, Issue.SUPPL.
, pp. 1995-2025
-
-
Sonis, S.T.1
Elting, L.S.2
Keefe, D.3
-
9
-
-
34548680047
-
Establishment of a single dose irinotecan model of gastrointestinal mucositis
-
Gibson RJ, Bowen JM, Alvarez E, et al. Establishment of a single dose irinotecan model of gastrointestinal mucositis. Chemotherapy 2007; 53: 360-369.
-
(2007)
Chemotherapy
, vol.53
, pp. 360-369
-
-
Gibson, R.J.1
Bowen, J.M.2
Alvarez, E.3
|